Cargando…
Bioanalytical method development and validation of HPLCUV assay for the quantification of SHetA2 in mouse and human plasma: Application to pharmacokinetics study
BACKGROUND: SHetA2 is an oral anticancer agent being investigated for cancer treatment and prevention. The aim of this study was to develop and validate a simple, cost-effective, and sensitive HPLC-UV method for the quantification of SHetA2 in biological samples and to apply the method to pharmacoki...
Autores principales: | Sharma, Ankur, Thavathiru, Elangovan, Benbrook, Doris Mangiaracina, Woo, Sukyung |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5922436/ https://www.ncbi.nlm.nih.gov/pubmed/29708233 http://dx.doi.org/10.7243/2050-120X-6-2 |
Ejemplares similares
-
Pharmacokinetics and interspecies scaling of a novel, orally-bioavailable anti-cancer drug, SHetA2
por: Sharma, Ankur, et al.
Publicado: (2018) -
SHetA2 Attack on Mortalin and Colleagues in Cancer Therapy and Prevention
por: Benbrook, Doris Mangiaracina
Publicado: (2022) -
Utility and Mechanism of SHetA2 and Paclitaxel for Treatment of Endometrial Cancer
por: Chandra, Vishal, et al.
Publicado: (2021) -
Distinct mechanism of cervical cancer cell death caused by the investigational new drug SHetA2
por: Rai, Rajani, et al.
Publicado: (2022) -
SHetA2 interference with mortalin binding to p66shc and p53 identified using drug-conjugated magnetic microspheres
por: Benbrook, Doris Mangiaracina, et al.
Publicado: (2013)